Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Planchard

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
ESMO Open|September 20, 2021
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 studyD Planchard, P-H Feng, N Karaseva, et al.
British Journal of Cancer|August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasF Farace, C Massard, N Vimond, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 11, 2020
[Role of immunotherapy in locally advanced non-small cell lung cancer]A Levy, J Doyen, A Botticella, et al.
Lung Cancer (Amsterdam, Netherlands)|September 11, 2020
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasmsM Rubino, J Y Scoazec, E Pisa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Chest|September 26, 2025
The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" StudyPauline Pradère, A Marinello, D Vasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
Endocrine-Related Cancer|March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinomaJ Hadoux, D Malka, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2020
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerD Planchard, N Reinmuth, S Orlov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
ESMO Open|September 20, 2021
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 studyD Planchard, P-H Feng, N Karaseva, et al.
British Journal of Cancer|August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasF Farace, C Massard, N Vimond, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 11, 2020
[Role of immunotherapy in locally advanced non-small cell lung cancer]A Levy, J Doyen, A Botticella, et al.
Lung Cancer (Amsterdam, Netherlands)|September 11, 2020
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasmsM Rubino, J Y Scoazec, E Pisa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
Chest|September 26, 2025
The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" StudyPauline Pradère, A Marinello, D Vasseur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
Endocrine-Related Cancer|March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinomaJ Hadoux, D Malka, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2020
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerD Planchard, N Reinmuth, S Orlov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Pageof 6